Address How to Deal with Flu Season with Effective Treatment

Main Article Content

Aduwera Akerele Snema

Abstract

This examine examines the effectiveness of influenza control techniques via a quantitative evaluation of clinical consequences and remedy variables. A cohort of 500 individuals supplying with influenza signs was retrospectively analyzed to evaluate the effect of antiviral therapy, hospitalization quotes, headaches, and symptom decision time. Results indicate that set off initiation of antiviral therapy, with a median time to remedy initiation of 1. Eight days, turned into associated with favorable consequences and decreased headaches. However, 20% of contributors required hospitalization, highlighting the severity of influenza infection. Complications had been determined in 10% of cases. Symptom decision averaged 5.2 days, underscoring the various nature of influenza shows. Vaccination repute found out that forty% of individuals had been vaccinated, emphasizing the importance of vaccination as a safety measure. Overall, the findings underscore the complexity of influenza control and the want for tailored tactics to optimize results. These insights inform techniques to decorate vaccination uptake, improve remedy timing, and mitigate influenza-related morbidity and mortality.

Article Details

How to Cite
Snema, A. A. (2023). Address How to Deal with Flu Season with Effective Treatment. Journal of Community Health Provision, 3(3), 78-84. https://doi.org/10.55885/jchp.v3i3.301
Section
Articles

References

Berry, L., Lansbury, L., Gale, L., Carroll, A. M., & Lim, W. S. (2020). Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is associated with improvement in isolation practices and reduction in hospital length of stay. Journal of medical microbiology, 69(5), 697. https://doi.org/10.1099/jmm.0.001187

Bonnevie, E., Rosenberg, S. D., Kummeth, C., Goldbarg, J., Wartella, E., & Smyser, J. (2020). Using social media influencers to increase knowledge and positive attitudes toward the flu vaccine. Plos one, 15(10), e0240828. https://doi.org/10.1371/journal.pone.0240828

Chayrov, R., Parisis, N. A., Chatziathanasiadou, M. V., Vrontaki, E., Moschovou, K., Melagraki, G., ... & Stankova, I. (2020). Synthetic Analogues of Aminoadamantane as Influenza Viral Inhibitors—In Vitro, In Silico and QSAR Studies. Molecules, 25(17), 3989. https://doi.org/10.3390/molecules25173989

El-Sayes, N., Vito, A., & Mossman, K. (2021). Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers, 13(4), 806.

Gupta, S., Gupta, T., & Gupta, N. (2022). Global respiratory virus surveillance: strengths, gaps, and way forward. International Journal of Infectious Diseases, 121, 184-189. https://doi.org/10.1016/j.ijid.2022.05.032

Hrusak, O., Kalina, T., Wolf, J., Balduzzi, A., Provenzi, M., Rizzari, C., ... & Schrappe, M. (2020). Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 132, 11-16. https://doi.org/10.1016/j.ejca.2020.03.021

Jones, J. C., Yen, H. L., Adams, P., Armstrong, K., & Govorkova, E. A. (2023). Influenza antivirals and their role in pandemic preparedness. Antiviral Research, 210, 105499.

Liu, X., Zhang, B., Wang, Y., Haymour, H. S., Zhang, F., Xu, L. C., ... & Low, P. S. (2020). A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nature communications, 11(1), 5597. https://doi.org/10.1038/s41467-020-19386-5

Moehling Geffel, K., Christian, S. N., Casas, A. D., Dyer, H. P., Gary-Webb, T. L., Hardy, H. E., ... & Mendez, D. D. (2023). Perspectives on flu vaccination advertisement messaging in the era of COVID-19: Thematic analysis centering adult Black voices. Journal of Health Disparities Research and Practice, 16(2), 4.

Niessen, W. M. A. (2020). Tandem mass spectrometry of small-molecule antiviral drugs: 3. antiviral agents against herpes, influenza and other viral infections. International Journal of Mass Spectrometry, 455, 116377.

Nuwarda, R. F., Alharbi, A. A., & Kayser, V. (2021). An overview of influenza viruses and vaccines. Vaccines, 9(9), 1032. https://doi.org/10.3390/vaccines9091032

Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., ... & Horwitz, L. I. (2020). Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. MedRxiv, 2020-04.

Prado, C. M., Purcell, S. A., & Laviano, A. (2020). Nutrition interventions to treat low muscle mass in cancer. Journal of cachexia, sarcopenia and muscle, 11(2), 366-380. https://doi.org/10.1101/2020.04.08.20057794

Ryu, S., & Cowling, B. J. (2021). Human influenza epidemiology. Cold Spring Harbor Perspectives in Medicine, 11(12), a038356. https://doi.org/10.1101/cshperspect.a038356

Sands, P., & Winters, J. (2021). Countering the pandemic threat through global coordination on vaccines: the influenza imperative. National Academies of Sciences, Engineering, and Medicine. Https://doi.org/10.17226/26284

Verbakel, J. Y., Matheeussen, V., Loens, K., Kuijstermans, M., Goossens, H., Ieven, M., & Butler, C. C. (2020). Performance and ease of use of a molecular point-of-care test for influenza A/B and RSV in patients presenting to primary care. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1453-1460. https://doi.org/10.1007/s10096-020-03860-5

Villgran, V. D., Lyons, C., Nasrullah, A., Abalos, C. C., Bihler, E., & Alhajhusain, A. (2022). Acute respiratory failure. Critical care nursing quarterly, 45(3), 233-247. https://doi.org/10.1097/CNQ.0000000000000408

Wang, J., Sun, Y., & Liu, S. (2022). Emerging antiviral therapies and drugs for the treatment of influenza. Expert Opinion on Emerging Drugs, 27(4), 389-403.